Vancouver, Canada, May 05, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a European patent application for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. The European patent application forms part of the Company’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). Under the terms of the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and...

Active Trial Reflects Expansion into Telecom Segment TORONTO, May 05, 2026 (GLOBE NEWSWIRE) — BrandPilot AI Inc. (CSE: BPAI) (OTCQB: BPAIF) (“BrandPilot” or the “Company”), a performance marketing technology company focused on improving efficiency in digital advertising, today announced that a U.S.-based telecommunications provider has selected BrandPilot’s technology and entered an active trial across select digital campaigns. The work will focus on improving the quality of campaign signals, increasing audience precision, and enabling more efficient allocation of marketing spend across automated advertising channels. By addressing inefficiencies at the data and execution level, BrandPilot’s platform is designed to support more consistent and reliable performance outcomes at scale. “Telecommunications campaigns run at a scale where...

SYDNEY, Australia, May 05, 2026 (GLOBE NEWSWIRE) — GMEX Robotics Corporation (NASDAQ: GMEX) (“GMEX Robotics” or the “Company”), a developer of AI-powered robotic technologies, today announced it has received its first deployment order under its previously disclosed AU$4.2 million agreement with a leading Australian hospitality food and beverage group. The initial purchase order includes multiple Bon Vivant 3.0 automated cooking systems, representing approximately AU$504,000 in value. Delivery of the systems is expected to be completed prior to June 30, 2026. The order represents the first phase of execution under the purchase agreement announced on March 23, 2026, which provides for the planned deployment of at least 50 intelligent kitchen robotics systems, including Bon Vivant 3.0 and Max models, across the customer’s network of...

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at a purchase price of $7.00 per share to a single investor.   The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $7 million. Clene expects to use the net proceeds from the offering, together with its existing cash, for expenses...

TORONTO, May 05, 2026 (GLOBE NEWSWIRE) — Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”) advises that it has agreed with Waratah Capital Advisors Ltd. (“Waratah”) to extend to May 20, 2026 the date by which the Company must respond to the requisition received from Waratah on April 13, 2026. In the requisition, Waratah requested that the board of directors of Lithium Ionic call a special meeting of shareholders to remove Hélio Diniz, David Gower and Lawrence Guy as directors of the Company, and to consider and to vote on the election of directors to fill the vacancies created. As announced by the Company on April 20, 2026, Messrs. Diniz, Gower and Guy have resigned as directors of the Company. The board of directors intends to engage with Waratah and with other shareholders in connection...

Company signed term sheet for strategic investment and technology synergy with VisionWave NESS ZIONA, Israel, May 05, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced that it has strengthened its product proposition for the defense, homeland security and commercial infrastructure markets through a non-binding term sheet for strategic investment and technology integration with VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave”). The collaboration intends to integrate Foresight’s high-resolution visible light/infra-red and neuromorphic event-based sensor suite delivering ultra-low-latency detection in fast, dynamic, or low-light conditions for tactical and autonomous use cases into VisionWave’s multi-layered defense,...

Since Board announced appointment of CEO Hillary Super, Company has delivered total shareholder returns of 164%, outperforming the S&P 500 Consumer Discretionary Distribution Retail Index by 124% and peers used by research analysts by 172% Brett Blundy’s campaign follows Board’s decision not to appoint him as a director Board conducted a comprehensive review of Mr. Blundy’s candidacy which identified significant reputational, legal, conflict of interest and governance risks REYNOLDSBURG, Ohio, May 05, 2026 (GLOBE NEWSWIRE) — The Board of Directors (the “Board”) of Victoria’s Secret & Co. (the “Company”) (NYSE: VSCO) today shared the following update regarding BBRC International Pte Limited’s (“BBRC”) and its Chairman Brett Blundy’s decision to launch a proxy contest seeking to withhold votes against two directors at the...

SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that Alfred Hospital is now actively enrolling participants in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company’s lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). To date, four patients have been enrolled and dosed at Mackay Base Hospital in Queensland, Australia, the first site activated in the trial. Concussion and mild traumatic brain injury represent the most prominent neurological condition without an FDA-approved pharmacological treatment. According to the CDC, an estimated 1.7 to 3.8 million people in the U.S. experience traumatic brain...

HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) — Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) today announced it has been awarded multiple managed pressure drilling (“MPD”) contracts and a global aftermarket agreement with Noble Corporation (“Noble”), further strengthening the long-standing relationship between the two companies and reinforcing Weatherford’s leadership in MPD systems and lifecycle support. The awards include the delivery of two deepwater managed pressure drilling systems to support Noble’s Guyana operations, with delivery expected before year-end. Weatherford is also executing an upgrade on a third-party MPD system that is being assembled and configured at the Company’s Managed Pressure Wells Center of Excellence in Houston with deployment to Nigeria expected in the third quarter. In addition,...